Neoadjuvant chemotherapy (NCT) is often used for patients with early-stage breast cancer. Disparities in the use of NCT based on clinical, demographic, and socioeconomic factors have not been evaluated.
Methods
Data from the National Cancer Database was analyzed for patients with T1-2, N0-1 breast cancer from 2006 to 2015. Univariate and multivariate analysis determined which factors predicted for the receipt of NCT.
Results
We found 159 946 eligible patients. Factors associated with receipt of NCT included T2 vs. T1 disease, N1 vs. N0, and treatment at an academic facility. Race itself was not significant; however, a higher level of education amongst Black populations correlated with the receipt of NCT.
Discussion
Clinical factors are the greatest determinants for receipt of NCT in early-stage breast cancer. Disparities exist that cannot be explained by race alone; socioeconomic and demographic factors are important. Cancer care should be evaluated in the context of the intersectionality of these health determinants.
American Cancer Society. Breast Cancer Facts & Figures 2019-2020. Atlanta: American Cancer Society, Inc.; 2019.
2.
GralowJRBursteinHJWoodW, et al.Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(5):814-819. doi:10.1200/JCO.2007.15.3510
3.
MamtaniABarrioAVKingTA, et al.How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;23(11):3467-3474. doi:10.1245/s10434-016-5246-8
4.
MamounasEPUntchMManoMS, et al.Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: Subgroup analyses from katherine. Ann Oncol Off J Eur Soc Med Oncol. 2021;32(8):1005-1014. doi:10.1016/j.annonc.2021.04.011
5.
MasudaNLeeSJOhtaniS, et al.Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147-2159. doi:10.1056/NEJMoa1612645
6.
MetsEJChouairiFKGabrickKSAvrahamTAlperovichM. Persistent disparities in breast cancer surgical outcomes among hispanic and African American patients. J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2019;45(4):584-590. doi:10.1016/j.ejso.2019.01.016
7.
CoroneosCJLinYLSidey-GibbonsC, et al.Correlation between financial toxicity, quality of life, and patient satisfaction in an insured population of breast cancer surgical patients: A single-institution retrospective study. J Am Coll Surg. 2021;232(3):253-263. doi:10.1016/j.jamcollsurg.2020.10.023
8.
FayanjuOMRenYStashkoI, et al.Patient-reported causes of distress predict disparities in time to evaluation and time to treatment after breast cancer diagnosis. Cancer. 2021;127(5):757-768. doi:10.1002/cncr.33310
9.
DreyerMSNattingerABMcGinleyELPezzinLE. Socioeconomic status and breast cancer treatment. Breast Cancer Res Treat. 2018;167(1):1-8. doi:10.1007/s10549-017-4490-3
10.
BabatundeOAEberthJMFelderT, et al.Social determinants of racial disparities in breast cancer mortality among black and white women. J Racial Ethn Health Disparities. 2021;8(1):147-156. doi:10.1007/s40615-020-00766-y
11.
EmersonMAGolightlyYMAielloAE, et al.Breast cancer treatment delays by socioeconomic and health care access latent classes in Black and White women. Cancer. 2020;126(22):4957-4966. doi:10.1002/cncr.33121
12.
DeSantisCEMillerKDGoding SauerAJemalASiegelRL. Cancer statistics for African Americans. CA Cancer J Clin. 2019;69(3):211-233. doi:10.3322/caac.21555
13.
CharlsonMECarrozzinoDGuidiJPatiernoC. Charlson comorbidity index: A critical review of clinimetric properties. Psychother Psychosom. 2022;91(1):8-35. doi:10.1159/000521288
14.
PiccartMProcterMFumagalliD, et al.Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer in the aphinity trial: 6 years’ follow-up. J Am Soc Clin Oncol. 2021;39(13):1448-1457. doi:10.1200/JCO.20.01204
15.
KojimaGIliffeSWaltersK. Frailty index as a predictor of mortality: A systematic review and meta-analysis. Age Ageing. 2018;47(2):193-200. doi:10.1093/ageing/afx162
16.
RappJTuminelloSAlpertNFloresRMTaioliE. Disparities in surgery for early-stage cancer: The impact of refusal. Cancer Causes Control CCC. 2019;30(12):1389-1397. doi:10.1007/s10552-019-01240-9
17.
SilberJHRosenbaumPRRossRN, et al.Disparities in breast cancer survival by socioeconomic status despite medicare and medicaid insurance. Milbank Q. 2018;96(4):706-754. doi:10.1111/1468-0009.12355
18.
Reeder-HayesKEMayerSEOlshanAF, et al.Race and delays in breast cancer treatment across the care continuum in the Carolina breast cancer study. Cancer. 2019;125(22):3985-3992. doi:10.1002/cncr.32378
19.
JaiswalKHullMFurnissALDoyleRGayouNBaylissE. Delays in diagnosis and treatment of breast cancer: A safety-net population profile. J Natl Compr Cancer Netw JNCCN. 2018;16(12):1451-1457. doi:10.6004/jnccn.2018.7067
20.
GuJGrootGBodenCBuschAHoltslanderLLimH. Review of factors influencing women’s choice of mastectomy versus breast conserving therapy in early stage breast cancer: A systematic review. Clin Breast Cancer. 2018;18(4):e539-e554. doi:10.1016/j.clbc.2017.12.013
